Roche Uses Recursion AI to Uncover New Brain Disease Targets

Roche Bets on Recursion AI to Develop New Neuroscience Drug A new generation of AI companies believes it can reduce the number of failed drug trials. This article is for subscribers only. Welcome to Bloomberg’s AI Today newsletter. Every weekday we’ll break down artificial intelligence’s threats and opportunities for businesses, workers, finance and economies. Sign up now if you’re not already on the list. Imagine trying to invent a new medicine without knowing what causes the disease in the first place. That’s the reality for much of neuroscience. Researchers still don’t fully understand why diseases like Alzheimer’s or Parkinson’s develop, so drugmakers keep returning to the same shortlist of biological targets. If those don’t work — and most don’t — what’s a researcher to do next?